Specialist advice on this increasingly important topic

... one that encroaches into matters of privitisation, guarantees, commercial contracts, subsidies, tax, healthcare, Real Estate development and environmental issues.

Our State Aid experts assist clients in their consideration of the availability of State Aid, help determine whether notification to the European Commission is necessary; represent clients in litigation involving State Aid issues and in their discussions and negotiations with both the State and the European Commission.


25 July 2022

EU foreign subsidy control regime on the horizon: co-legislatures reach agreement

The European Parliament and Council of the EU have agreed on a draft text for the upcoming Foreign Subsidies Regulation (FSR). The FSR is intended to fix a regulatory asymmetry: state aid granted by EU member states is subject to strict checks, but there is no equivalent scrutiny of financial contributions by third countries to companies active in the EU. The FSR will make M&A deals or public procurement bids fuelled by foreign financial contributions notifiable to the European Commission if they meet certain thresholds. Notified M&A deals will remain suspended, and procurement contracts cannot be awarded, until there is a clearance decision from the Commission. Even when the notification thresholds are not met, the Commission might "call in" M&A deals before their implementation or bids before the award of the public contract. Under a general market investigation power, the Commission may also review implemented concentrations or awarded public contracts. In practice, this means dealmakers will have to navigate a variety of regimes and jurisdictions as an M&A deal could be subject to national or EU merger control, national security/foreign direct investment (FDI) control, and now also, EU foreign subsidy control.
18 May 2021

EU proposes foreign subsidy control to match internal state aid regime

While state aid from EU member states is scrutinised on its compatibility with the internal market, there is no corresponding review framework for financial support provided by non-EU states to undertakings that are active in the EU. This can cause certain undertakings to receive foreign subsidies from third countries while others may be prohibited from getting financial aid from EU member states. Foreign subsidies could, for example, allow undertakings to offer lower sales prices in the EU or outbid competitors in M&A transactions. The European Commission has responded with a proposal to level the playing field. The proposal contains a standstill obligation, meaning companies which received foreign subsidies will have to notify the Commission and await clearance before bidding in an M&A deal. Contracting authorities that encounter participants which received foreign subsidies in their public procurements must also notify. Financial thresholds have been set for both types of notification procedures. However, even where cases fall below the threshold, they might still attract scrutiny if the Commission believes their potential impact in the EU so merits.
20 March 2020

Coronavirus and competition law - state aid, merger control, crisis cartels and price hikes

Competition law has an important role to play in assessing the legitimacy of economic actions taken by EU member states and businesses in dealing with the impact of the coronavirus. National measures to mitigate economic harm may constitute state aid, which has to be approved by the Commission. The Commission has adopted a temporary framework to test the compatibility of national measures with EU state aid rules. M&A deals are also affected as competition authorities are calling on companies not to submit new notifications, while some ongoing reviews have been paused. Stand-still obligations stay in place, but an exemption might be available if the target company is in serious financial difficulty. Competition authorities are supportive of sector-wide initiatives that are justified in view of the new challenges, such as those in the supermarket and pharmaceutical sectors. But they will remain vigilant in identifying anti-competitive behaviour that can result in price hikes.